Clinical Trial Update: Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial, sponsored by Zhengzhou University, is evaluating a CEP+dasatinib+azacitidine regimen as first-line therapy for angioimmunoblastic T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• CEP
• DASATINIB (Dasatinib)

Snippet

Sponsor: Zhengzhou University | Conditions: Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 4 | Status: ACTIVE_NOT_RECRUITING